Philip J. Mease

76.5k citations

800 papers · 39.2k indexed · 19 hit papers · h-index 90

Rheumatology top 0.01%
Immunology top 0.02%
Hematology top 0.01%
Psychiatry and Mental health top 0.05%
Pharmacology top 0.02%

Co-authors: Dafna D. Gladman Daniel J. Clauw Philip Helliwell I. Jon Russell Désirée van der Heijde Don L. Goldenberg Mary‐Ann Fitzcharles Anthony S. Russell
Topics: Spondyloarthritis Studies and Treatments (572 papers)Psoriasis: Treatment and Pathogenesis (476 papers)Rheumatoid Arthritis Research and Therapies (400 papers)
Cited by: Rheumatology Hematology Immunology
Journals: New England Journal of Medicine The Lancet Nature Medicine
Partner nations: United States United Kingdom Canada

In The Last Decade

Philip J. Mease

774 papers receiving 38.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity

2010 2.9k citations Philip J. Mease et al. Arthritis Care & Research profile →
Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

2006 2.6k citations Dafna D. Gladman, Philip Helliwell et al. profile →
2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria

2016 1.4k citations Philip J. Mease et al. profile →
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

2000 1.1k citations Philip J. Mease et al. profile →
Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

2011 1.1k citations Philip J. Mease et al. The Journal of Rheumatology profile →
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial

2005 702 citations Philip J. Mease, Dafna D. Gladman et al. profile →
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

2004 697 citations Philip J. Mease et al. profile →
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. profile →
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

2015 572 citations Philip J. Mease, Iain B. McInnes et al. profile →
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study

2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

2009 462 citations Iain B. McInnes, Philip J. Mease et al. profile →
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

2017 421 citations Philip J. Mease, Oliver FitzGerald et al. profile →
Patient perspectives on the impact of fibromyalgia

2008 401 citations Philip J. Mease et al. profile →
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

2014 341 citations Arthur Kavanaugh, Philip J. Mease et al. Annals of the Rheumatic Diseases profile →
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

2020 242 citations Philip J. Mease, Proton Rahman et al. profile →
Psoriatic arthritis

2021 190 citations Oliver FitzGerald, Alexis Ogdie et al. profile →
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

2023 124 citations Peter Nash, Atul Deodhar et al. RMD Open profile →

Peers

Countries citing papers authored by Philip J. Mease

Since Specialization

Citations

This map shows the geographic impact of Philip J. Mease's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Mease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Mease more than expected).

Fields of papers citing papers by Philip J. Mease

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Mease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Mease. The network helps show where Philip J. Mease may publish in the future.

Co-authorship network of co-authors of Philip J. Mease

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Mease. A scholar is included among the top collaborators of Philip J. Mease based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Mease. Philip J. Mease is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis 2025 ·Arthritis Care & Research ·(unknown),Jordi Pardo Pardo,Shaonong Dang,Lianne S. Gensler,Philip J. Mease,Lihi Eder	1
2	Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry 2024 ·Rheumatology and Therapy ·Philip J. Mease,(unknown),Lara Fallon,Rajiv Mundayat,Oluwaseyi Dina,Taylor Blachley,(unknown),Alexis Ogdie	3
3	Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison 2024 ·Rheumatology and Therapy ·Philip J. Mease,Richard B. Warren,Peter Nash,Jean‐Marie Grouin,(unknown),V. Taieb,(unknown),Iain B. McInnes	1
4	Prevalence of Fibromyalgia and Widespread Pain in Psoriatic Arthritis: Association With Disease Severity Assessment in a Large US Registry 2024 ·Arthritis Care & Research ·Philip J. Mease,George Reed,Alexis Ogdie,Dimitrios A. Pappas,Joel M. Kremer	7
5	Improvements in Patient‐Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial 2024 ·Arthritis Care & Research ·Vibeke Strand,Laure Gossec,Laura C. Coates,Alexis Ogdie,Jiyoon Choi,Brandon Becker,(unknown),Thomas Lehman,Miroslawa Nowak,Ayanbola Elegbe,Philip J. Mease,Atul Deodhar	1
6	Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials 2024 ·ACR Open Rheumatology ·Arthur Kavanaugh,Philip J. Mease,Laure Gossec,Roberto Ranza,Shigeyoshi Tsuji,Kevin Douglas,Michael Lane,Ralph Lippe,Manish Mittal,Tianming Gao,Arathi R. Setty,(unknown),Daniel Aletaha,Peter Nash	2
7	POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL 2023 ·Annals of the Rheumatic Diseases ·Iain B. McInnes,Philip J. Mease,Yoshiya Tanaka,Frank Behrens,Laure Gossec,M. Elaine Husni,Lars Erik Kristensen,Richard B. Warren,Barbara Ink,Rajan Bajracharya,Jason Coarse,(unknown),Alice B. Gottlieb	3
8	AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2023 ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,(unknown),(unknown),M. Shawi,Elena Schiopu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	2
9	Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting 2023 ·The Journal of Rheumatology ·Beverly Ng,Deepak R. Jadon,Frank Behrens,Maarten de Wit,Oliver FitzGerald,Dafna D. Gladman,Philip J. Mease,D. C. O'SULLIVAN,Stephen R. Pennington,Georg Schett,Vinod Chandran,Kurt de Vlam	1
10	Project Highlights From the GRAPPA 2022 Annual Meeting: Education Initiatives and Axial Involvement in Psoriatic Arthritis 2023 ·The Journal of Rheumatology ·Murat Torğutalp,Dafna D. Gladman,Oliver FitzGerald,Philip J. Mease,Denis Poddubnyy	2
11	Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry 2023 ·Rheumatology and Therapy ·Philip J. Mease,Alexis Ogdie,John Tesser,Natalie J. Shiff,(unknown),Soumya D. Chakravarty,Michael Kelleman,(unknown),Robert R. McLean,(unknown),Arthur Kavanaugh,Joseph F. Merola	9
12	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies 2022 ·RMD Open ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,Elena Schiopu,Soumya D. Chakravarty,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,(unknown),Shihong Sheng,Yanli Wang,Stephen Xu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	18
13	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group 2022 ·The Journal of Rheumatology ·(unknown),Richard Holland,Ashish Jacob Mathew,Maria Antonietta D’Agostino,Walter P. Maksymowych,Philip J. Mease,Niti Goel,Alexis Ogdie,Laura C. Coates,Vibeke Strand,Robin Christensen,Dafna D. Gladman,Ana‐Maria Orbai,Ying Ying Leung,William Tillett	4
14	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey 2021 ·The Journal of Rheumatology ·Anne Boel,Victoria Navarro‐Compán,Annelies Boonen,Philip J. Mease,Uta Kiltz,Maxime Dougados,Robert Landewé,Désirée van der Heijde	5
15	GRAPPA 2018 Project Report 2019 ·The Journal of Rheumatology ·Niti Goel,Oliver FitzGerald,Dafna D. Gladman,Philip Helliwell,Arthur Kavanaugh,Walter P. Maksymowych,Philip J. Mease,Christopher T. Ritchlin,Laura C. Coates	6
16	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 2019 ·Lara D. Veeken ·Désirée van der Heijde,Philip J. Mease,Robert Landewé,Proton Rahman,Hasan Tahir,Atul Singhal,(unknown),Sandra Navarra,Xuan Zhu,Gregory Ligozio,Aimee Readie,Shephard Mpofu,Luminita Pricop	45
17	4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis 2018 ·RMD Open ·Désirée van der Heijde,Atul Deodhar,Oliver FitzGerald,Roy Fleischmann,Dafna D. Gladman,Alice B. Gottlieb,Bengt Hoepken,Lars Bauer,(unknown),Majed Khraishi,Luke Peterson,Anthony Turkiewicz,J. Wollenhaupt,Philip J. Mease	30
18	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry 2017 ·The Journal of Rheumatology ·Philip J. Mease,Chitra Karki,Jacqueline B. Palmer,Carol J. Etzel,Arthur Kavanaugh,Christopher T. Ritchlin,Wendi Malley,Vivian Herrera,(unknown),Jeffrey D. Greenberg	19
19	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Meeting 2013 ·The Journal of Rheumatology ·Philip J. Mease,Amit Garg,Dafna D. Gladman,Philip Helliwell	8
20	Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria 2012 ·Data Archiving and Networked Services (DANS) ·Walter P. Maksymowych,(unknown),Robert Landewé,(unknown),Joan M. Bathon,(unknown),Vivian P. Bykerk,Mikkel Østergaard,Hilde Berner Hammer,(unknown),(unknown),Oliver FitzGerald,Christopher T. Ritchlin,Dafna D. Gladman,Philip J. Mease,(unknown),M. Backhaus,Bernard Combe,(unknown),A. Marotta	2

About Philip J. Mease

Philip J. Mease is a scholar working on Rheumatology, Hematology and Immunology, having authored 800 papers that have together received 39.2k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (572 papers), Psoriasis: Treatment and Pathogenesis (476 papers) and Rheumatoid Arthritis Research and Therapies (400 papers). The work is most often cited by research in Rheumatology (23.4k citations), Hematology (12.5k citations) and Immunology (19.7k citations). Philip J. Mease has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Dafna D. Gladman, Daniel J. Clauw, Philip Helliwell, I. Jon Russell, Désirée van der Heijde, Don L. Goldenberg, Mary‐Ann Fitzcharles, Anthony S. Russell, William J. Taylor and Christopher T. Ritchlin. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact